Article content
SEOUL Samsung BioLogics Co Ltd and Pfizer Inc on Wednesday denied a report that they were working together to produce in South Korea a COVID-19 vaccine developed by the U.S. drugmaker.
The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer vaccine, which was jointly developed by the German BioNTech.
We apologize, but this video has failed to load.
Try refreshing your browser, or Samsung BioLogics, Pfizer deny report on COVID-19 vaccine production in S.Korea Back to video
The report quoted an unnamed high-level government official as saying the plant had the capacity to make up to 1 billion doses per year and production could start as early as in August.
Samsung Biologics Reports First Quarter 2021 Financial Results
News provided by
Share this article
Q1 21 operating profit of KRW 74.3 billion increased 19% compared to Q1 20.
Q1 21 operating margin held steady at 28%.
All manufacturing facilities remain fully operational, without any disruptions caused by the COVID-19 pandemic.
Construction for the new Plant 4 stays on track with active pre-sales forecast.
INCHEON, South Korea, April 28, 2021 /PRNewswire/ Samsung Biologics (KRX: 207940.KS), the world s leading contract development and manufacturing organization, today announced financial results for the first quarter of fiscal 2021.
John Rim, CEO of Samsung Biologics, stated, Our first-quarter financial performance was in line with our expectations and provides us with a strong start to the 2021 fiscal year. We have maintained a solid performance, and continue to see momentum from our expanding CDMO business globally while simultaneously making continuous advancements
Samsung Biologics Reports First Quarter 2021 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
Expanding upon an existing contract manufacturing deal first entered into in 2018; collaboration will further enable global manufacturing of ublituximab
News provided by
Share this article
Share this article
INCHEON, South Korea and NEW YORK, April 25, 2021 /PRNewswire/ Samsung Biologics (KRX: 207940.KS), the world s leading contract development and manufacturing organization and TG Therapeutics (NASDAQ: TGTX), today announced an expansion of a large-scale contract manufacturing deal for the supply of TG Therapeutics ublituximab, an investigational anti-CD20 monoclonal antibody. TG Therapeutics has completed a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, in combination with UKONIQ™ (umbralisib), TG Therapeutics oral once-daily inhibitor of PI3K-delta and CK1-epsilon, a